drugset / Trial / NCT05972460
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
Phase 1
Unknown
108 enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Fudan University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is a first-in-human, open-label, multi-center, dose escalation phase 1a study followed by cohort expansion phase 1b study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced solid tumors.
Timeline
- Start
- 2021-08-18
- Primary completion
- 2023-12
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 0.007 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 0.03 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 0.1 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 20 mg/kg | Intravenous |